Triage DD of short bowel syndrome assets
Challenge:
For a mid-size European pharma company thinking of entering a new therapeutic area, we conducted ‘Triage’ level due diligence which focused only on publicly available information for three assets being developed for a specific indication.
Solution:
Using publicly-available information about each program, together with an analysis of the landscape in the particular indication we provided a high-level assessment in the following areas:
- Scientific rationale of the mechanism of action in the target indication
- Strength of proof-of-concept data
- Summary of regulatory status e.g., designations
- Market opportunity including competitive landscape and differentiation
We conducted the entire assessment within a one week timeframe.
Due Diligence Services
Alacrita's due diligence experts have conducted over 200 major assignments for large pharma, biotech, universities and investors, underpinned by our ability to ensure each due diligence exercise is supported by individuals with the precise expertise required for a complete, thorough and accurate assessment.
Related Case Studies
Explore similar engagements and see how we've helped other clients achieve their goals.
Pre-Due Diligence Assessment of First-in-Class Allergy Therapeutic
Strategic Partnership Assessment of Autoimmune Drug Development Program
Pre-Due Diligence Assessment of a Women's Health Biotech Partnership
Due Diligence of an Academic Adenovirus Gene-Therapy Program
Interested in Learning More?
Contact us to discuss how we can support your project with similar expertise.